Archive - February 2025
Certain Glucose-Lowering Meds Associated With Lower Risk for COPD Exacerbations
Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome
Acalabrutinib-Venetoclax Prolongs Survival in Previously Untreated Leukemia
Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome
Epidural Steroid Injections Reviewed for Radicular Pain, Spinal Stenosis
Satsuma Pharmaceuticals and SNBL Receive FDA Acceptance of NDA Resubmission of STS101 for the Acute Treatment of Migraine With or Without Aura
Olpasiran Leads to Significant Reduction in Oxidized Phospholipids
Black Patients With Cancer Still Have Higher Mortality Rates Than Whites